- Conditions
- Primary Dysmenorrhea
- Interventions
- One Unit TENS, Two Unit TENS
- Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 72
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
- Interventions
- cyclic microgestin 1/20, continuous microgestin 1/20
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 353 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Questionnaire Only
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Endometriosis, Pelvic Pain, Dysmenorrhea
- Interventions
- Manual Physical Therapy
- Other
- Lead sponsor
- Clear Passage Therapies, Inc
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Endometriosis
- Interventions
- NBI-56418 (GnRH antagonist), placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • San Diego, California • San Ramon, California + 12 more
- Conditions
- Endometriosis
- Interventions
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Endometriosis
- Interventions
- Placebo, OBE2109
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 71
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
- Conditions
- Uterine Fibroids, Leiomyoma, Menstrual Pain
- Interventions
- Elix Daily Harmony
- Dietary Supplement
- Lead sponsor
- Zenchi, Inc.
- Industry
- Eligibility
- 20 Years to 45 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine Fibroid
- Interventions
- Sildenafil citrate vaginal suppository
- Drug
- Lead sponsor
- Kevin Hellman
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Dysmenorrhea
- Interventions
- levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
- Drug
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
- Conditions
- Dysmenorrhea Primary
- Interventions
- Osteopathic manipulative medicine
- Procedure
- Lead sponsor
- New York Institute of Technology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Old Westbury, New York
- Conditions
- Primary Dysmenorrhea
- Interventions
- Quantitative Sensory Testing, fMRI
- Behavioral · Other
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 13 Years to 19 Years · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Dysmenorrhea
- Interventions
- Naproxen Sodium, (Aleve, BAY117031), Acetaminophen (Tylenol Extra Strength)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 15 Years to 35 Years · Female only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Pinellas Park, Florida + 5 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
- Conditions
- Primary Dysmenorrhea
- Interventions
- VA111913 TS and placebo
- Drug
- Lead sponsor
- Vantia Ltd
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Peoria, Arizona • Austin, Texas • Salt Lake City, Utah
- Conditions
- Menstrual Cramps, Women's Health, Fatigue
- Interventions
- My Happy Flo
- Dietary Supplement
- Lead sponsor
- My Happy Flo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Adenomyosis
- Interventions
- Vaginal Bromocriptine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 55 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
- Conditions
- Endometriosis
- Interventions
- Ulipristal
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Womens Health, Menstrual Symptoms
- Interventions
- Effera® (human equivalent lactoferrin), Placebo
- Dietary Supplement · Other
- Lead sponsor
- Helaina Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
- Interventions
- Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Evanston, Illinois